MICROFAT / LIPOGEMS — MICROFRAGMENTED ADIPOSE TISSUE
Microfat and Lipogems are the same concept: your own fat, broken down by machine and rinsed, then placed back into the joint. It takes one procedure, and the best follow-up data runs to four years.
How long does a microfat or Lipogems injection last?
This is the number that sets fat apart from everything else on this website. A prospective series followed patients with painful knee osteoarthritis. They had already failed conservative treatment. A single microfragmented fat injection still gave a clinically effective result in 68% of them at four years.
Set that against how platelet-rich plasma behaves. PRP delivers a burst of growth factors that get used up over weeks. The effect is real, and for most joints it lasts months and then is repeated. Fat is not a burst. It is a graft of living tissue with its own scaffold, and it stays where it is put.
That difference in kind is why the head-to-head trials are more hopeful than they first look. A randomized comparison found a single microfat injection did not differ from PRP for clinical outcomes out to 24 months. The honest way to read that is not “no better”. It is that one procedure held its own for two years against a treatment normally given as a series.
What is in a microfat injection, and why fat rather than bone marrow?
Adipose tissue (fat) is the most cell-dense tissue you can harvest from an awake patient. It comes out through a small cannula under local anesthetic. The repair cells do not live in the fat cells themselves. They live in the perivascular tissue around them — the vessel walls that thread through the fat. Fat carries far more of that per gram than marrow does.
The processing is mechanical on purpose. Tissue is broken up and rinsed of oil and blood. Nothing is digested with enzymes, cultured or grown. What comes back is a paste of intact fat clusters. Their blood-vessel niche and scaffold stay whole. That matters twice. It keeps the procedure inside minimal-manipulation rules as a same-day autologous treatment (made from you). And it keeps the structure that lets the graft stay in the joint instead of drifting out of it.
Lipogems (microfragmented fat) is the best-known device for doing this in the United States. Much of the published safety and outcome data comes from it. The brand names the machine, not a different substance. That is why microfat, micro-fragmented adipose tissue, MFAT and Lipogems all mean the same thing on this page.
Which joints does microfat work best for?
The case for fat gets stronger exactly where the case for plasma gets weaker.
Moderate-to-severe disease. A prospective cohort treated severe knee and shoulder osteoarthritis. It found significant gains on every outcome measure from two weeks, maintained at fifty-two weeks. In that group, a plasma preparation typically gives a shorter and smaller effect.
Against a steroid. A randomized trial enrolled 480 patients across Kellgren–Lawrence grades 2 through 4 (the X-ray arthritis scale). Some got a single cell-based injection. Others got a corticosteroid. At twelve months, the cell-based group was more likely to be counted as responders. They also avoided the cartilage cost that repeated steroid carries, set out on PRP compared with cortisone.
Beyond the knee. The knee has most of the evidence, but it is not the only joint. A prospective series in hip osteoarthritis used a single ultrasound-guided injection. It found significant improvement in pain and function at every follow-up point to a year. The shoulder data sits inside the severe-disease cohort above. The hip is a deep joint that cannot be reached reliably by feel. So for the hip in particular, a lasting graft plus image guidance is a sensible pairing. See PRP for hip osteoarthritis.
The one honest limitation, and why it argues for treating here
Two independent analyses have found the same thing: outcomes fall as body mass index rises. One looked inside the severe-OA cohort. It found that higher BMI went with less gain in the knee. The other, a secondary analysis of a randomized PRP-versus-microfat trial, looked at the same link directly.
Most clinics offering this will not tell you that. The ones that do tend to use it as a reason to turn people away. It is neither. It is the clearest possible evidence that an orthobiologic performs to the standard of the terrain you inject it into. Insulin resistance and metabolic inflammation glycate collagen (stiffen it with sugar). They weaken delivery through the small blood vessels and hold tissue in a breakdown state. That same mechanism, described in full on metabolic health and tissue repair, decides how any of this performs.
That is the argument for having it done somewhere that treats the metabolic picture at the same visit. Reading a bloodwork panel is not an add-on here. It is the reason the biology gets a fair chance. Some practices inject fat into an untreated metabolic problem. Then they call the result the treatment’s ceiling. They have confused the tissue with the terrain.
Who is a good candidate for Lipogems?
- Anyone who wants one procedure rather than a series. The durability data is the reason to choose it. One appointment instead of three is a real difference in a working life.
- Moderate to advanced degeneration, where plasma has less to work with. That is also where the four-year figures were earned.
- A joint that responded to PRP but not enough — partial, genuine, and short of what was needed.
- Anyone putting off a joint replacement who wants the years in between to be worth something. What that buys is set out on PRP compared with surgery.
It does not suit someone expecting it to do what an arthroplasty (joint replacement) does. It rebuilds no cartilage, and we will not claim it does.
What the day involves
A small area of the belly or flank is numbed, and tissue is drawn out through a cannula. It takes longer and is more uncomfortable than a blood draw. The honest warning is that the harvest site is usually sorer than the joint for the first few days. That is the price of the durability. It is worth naming before you agree to it, not after.
Processing happens in the room at the same visit. Nothing is shipped anywhere, nothing is stored, and nothing is cultured. The injection is placed under ultrasound or fluoroscopic guidance, because a paste this thick, placed by feel, is not reliably where you think it is. The recovery timeline applies as written, with a second sore site added to it.
What are the risks of a microfat injection?
A systematic review looked at side effects across cell-based knee injections — marrow, adipose, stromal vascular fraction and cultured products. It found the complication profile favorable. Serious events were uncommon. Everything on the general risks page applies. Add the two things that come with a graft. One is a second wound, with its own small risk of infection and bleeding. The other is more harm to the donor site than the phrase “a little fat” leads people to expect.
One thing this is not: a stem cell treatment, whatever the clinic down the road is calling it. Nothing is counted, cultured or grown. The honest description is a minimally manipulated autologous tissue graft. The line is drawn on PRP compared with stem cell treatments, and it matters more than the marketing suggests.
What people ask about a fat-based treatment
Is microfat the same as Lipogems?
Yes. Lipogems is the processing system most widely used in the United States. Much of the published data comes from it. Microfat, micro-fragmented adipose tissue and MFAT are the plain names for the same tissue made the same way. There is no difference in substance.
Is it better than PRP?
It lasts longer, which is the difference that matters. Head-to-head trials show a single microfat injection holding level with PRP out to 24 months. A separate series had 68% of patients still doing well at four years from one treatment. For a simple earlier-stage joint, PRP remains an excellent and less demanding option.
How many injections will I need?
Usually one. That is the main practical argument for it, and it is why the harvest is worth the trouble.
Does it hurt more than PRP?
Yes, and at the donor site more than the joint. Expect the belly or flank to be the sorer area for several days. The joint itself behaves much like any other guided injection.
Does my weight affect whether it works?
It does, and we say so. Outcomes fall as BMI rises in more than one analysis. That is not a reason to decline treatment. It is the reason we assess and treat the metabolic picture alongside it here, instead of leaving it as an unexamined ceiling on your result.
Related reading
- Bone marrow aspirate concentrate
- PRP compared with BMAC
- PRP compared with stem cell treatments
- Metabolic health and tissue repair
- PRP for knee osteoarthritis
- Recovery timeline
Ask whether one procedure beats a series for your joint
For a straightforward earlier-stage joint the smaller treatment is often right. Where durability is what you actually need, this is the conversation to have.
12174 Natural Bridge Rd, Suite 303
St. Louis, MO 63044
Next to DePaul Hospital, just off the 270 and 70 junction, west of the airport.
Sources
- Onorato F et al. Autologous microfragmented adipose tissue treatment of knee osteoarthritis demonstrates effectiveness in 68% of patients at 4-year follow-up. Arch Orthop Trauma Surg, 2024. PubMed 38212589
- Sgaglione NA et al. In Patients with Symptomatic Knee Osteoarthritis, a Single Intra-Articular Injection of Microfragmented Adipose Tissue Did Not Differ from Platelet-Rich Plasma for Clinical Outcomes at Up to 24 Months. J Bone Joint Surg Am, 2023. PubMed 36943927
- Mautner K et al. Autologous Cell Injections for Knee Osteoarthritis Display Greater Responsiveness Than Allogenic Cellular Products and Corticosteroids in a Sex-Dependent Manner. Am J Sports Med, 2025. PubMed 41014273
- Fan F et al. An observational study evaluating the efficacy of microfragmented adipose tissue in the treatment of osteoarthritis. Regen Med, 2023. PubMed 36541936
- Zaffagnini M et al. Micro-fragmented adipose tissue for the treatment of hip osteoarthritis: A prospective pilot study at 1-year follow-up. J Exp Orthop, 2025. PubMed 41473851
- Baria M et al. Relationship of Body Mass Index on Patient-Reported Outcomes After Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Secondary Analysis of a Randomized Controlled Trial. Am J Phys Med Rehabil, 2024. PubMed 38630921
- Zaffagnini S et al. Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. Am J Sports Med, 2022. PubMed 35984721
- Panchal J et al. Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knees. Am J Orthop (Belle Mead NJ), 2018. PubMed 30517209
- Riggle C et al. Complications of Stem Cell-Based Injections for Knee Osteoarthritis: A Systematic Review. HSS J, 2025. PubMed 39564419
- De Francesco F et al. Stem Cells in Autologous Microfragmented Adipose Tissue: Current Perspectives in Osteoarthritis Disease. Int J Mol Sci, 2021. PubMed 34638538
